After [losing out to Pfizer]( ...

Shares climbed as much as 3.5% in early European trade after Pfizer agreed to buy Metsera in a deal that could be worth more ...

Pedersen COPENHAGEN (Reuters) -Shares in Novo Nordisk rose on Monday after the Wegovy maker lost out to Pfizer in a $10 ...

NEW YORK/LONDON (Reuters) -U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping ...

Novo Nordisk has partnered with India's Emcure Pharmaceuticals to exclusively distribute and market weight-loss drug Poviztra ...

Novo Nordisk A/S posted solid revenue and profit increases, with a resilient pipeline and strong dividend yield. Learn more ...

Ever wondered if Novo Nordisk’s stock is a hidden bargain or already priced for perfection? Let’s break down what’s happening beneath the surface so you can invest with clarity. The stock has seen ...

Pfizer wins Metsera after antitrust warning derails Novo's $9B bid; investors reward financial discipline over deal chasing.

Danish drugmaker Novo Nordisk has teamed up with Emcure Pharmaceuticals to increase access to its weight-loss drug ...

This collaboration combines Novo Nordisk’s innovation in GLP-1 therapies with Emcure’s marketing and distribution strengths ...

On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an ...

Novo Nordisk stock rose 2.6% after withdrawing from a $10 billion bidding war for Metsera that investors viewed as too ...